Vanda Pharmaceuticals Stock Falls After Anxiety Drug Trial Fails

3-line summary

• Vanda Pharmaceuticals' on-demand anxiety drug VQW-765 failed its Phase 3 trial (Study 3201), which tested 546 adults with social anxiety disorder against placebo, per Investing.com. The primary endpoint showed no statistically significant difference in stress levels between VQW-765 and placebo during a performance task for female participants (p=0.8899), and a key secondary endpoint for the combined male-female population also failed (p=0.6605), despite numerical stress reductions seen in an earlier Phase 2 trial.
• Vanda said VQW-765 was safe and well-tolerated consistent with prior studies, but the drug's development program is now on hold pending further analysis of the full dataset. Shares fell 6.2% in after-hours trading.

This summary is our own processing of the source article; see the source link below for full context.